Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs

Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs

Source: 
Endpoints
snippet: 

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.